Zota Health Care Ltd
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company is expected to give good quarter
- +Company has been maintaining a healthy dividend payout of 49.3%
Weaknesses
- −Stock is trading at 8.73 times its book value
- −Promoter holding has decreased over last quarter: -1.25%
- −Company has a low return on equity of 4.32% over last 3 years.
- −Earnings include an other income of Rs.10.8 Cr.
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 64.44% | 62.4%▼2.0 | 62.02%▼0.4 | 59.72%▼2.3 | 57.42%▼2.3 | 55.81%▼1.6 | 50.64%▼5.2 | 49.38%▼1.3 |
| FIIs | 0.01% | 0.01% | 0.24%▲0.2 | 0.87%▲0.6 | 3.82%▲2.9 | 3.49%▼0.3 | 8.09%▲4.6 | 8.21%▲0.1 |
| DIIs | 0% | 0.99%▲1.0 | 1.03%▲0.0 | 3.08%▲2.0 | 4.25%▲1.2 | 4.95%▲0.7 | 7.22%▲2.3 | 6.4%▼0.8 |
| Public | 35.55% | 36.6%▲1.1 | 36.71%▲0.1 | 36.33%▼0.4 | 34.52%▼1.8 | 35.75%▲1.2 | 34.06%▼1.7 | 36%▲1.9 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41.15 | 42.83 | 47.35 | 52.2 | 59.01 | 68.13 | 77.93 | 78.01 | 99.42 | 108.88 |
| Expenses | 38.06 | 40.71 | 46.97 | 49.25 | 55.77 | 66.82 | 73.99 | 70.86 | 88.62 | 100.61 |
| Operating Profit | 3.09 | 2.12 | 0.38 | 2.95 | 3.24 | 1.31 | 3.94 | 7.15 | 10.8 | 8.27 |
| OPM % | 7.51% | 4.95% | 0.8% | 5.65% | 5.49% | 1.92% | 5.06% | 9.17% | 10.86% | 7.6% |
| Net Profit | 1.79 | 1.16 | 0.22 | 1.58 | 2.35 | 2.08 | 2.6 | 5.9 | 9.91 | 6.01 |
| EPS ₹ | 0.69 | 0.45 | 0.09 | 0.6 | 0.86 | 0.75 | 0.91 | 1.98 | 3.23 | 1.78 |
AI Insights
TTM revenue at ₹364Cr, up 42.2% YoY. OPM at 8%.
Borrowings at ₹2Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
CWIP at ₹7Cr (3% of fixed assets). Moderate ongoing capital expenditure.
DIIs: 6.4% (+6.40pp change). FIIs: 8.21% (+8.17pp change). Promoters hold 49.38%.
ROCE declining from 27% (Mar 2014) to 6% (Mar 2025). Working capital days: 177.
PE 170x with 5.68% ROCE. Price is 789% above book value of ₹135. Dividend yield: 0.08%.
Recent Announcements
- Monitoring Agency Report 14 May 2026 - CRISIL monitoring report for March 31, 2026 QIP shows no deviation; proceeds remain in fixed deposits.
- Monitoring Agency Report 14 May 2026 - CRISIL final monitoring report confirms full utilization of Rs179.07 crore preferential issue proceeds for quarter ended March 31, 2026.
- Shareholders meeting 17 April 2026 - Shareholders approved special resolution authorising loans, guarantees, securities and investments up to ₹1,000 crore.
- Certificate under SEBI (Depositories and Participants) Regulations, 2018 14 April 2026 - Zota Health Care filed Regulation 74(5) certificate for quarter ended March 31, 2026.
- Updates 13 April 2026 - Zota clarifies postal ballot seeking ₹1,000 crore Section 186 limits; voting runs Mar 18-Apr 16, 2026.
- Financial Year 2025 from nse
- Financial Year 2024 from nse
- Financial Year 2023 from nse